Literature DB >> 9613886

Risk of major hemorrhage for outpatients treated with warfarin.

D A McMahan1, D M Smith, M A Carey, X H Zhou.   

Abstract

OBJECTIVE: To determine the incidence of major hemorrhage among outpatients started on warfarin therapy after the recommendation in 1986 for reduced-intensity anticoagulation therapy was made, and to identify baseline patient characteristics that predict those patients who will have a major hemorrhage.
DESIGN: Retrospective cohort study.
SETTING: A university-affiliated Veterans Affairs Medical Center. PATIENTS: Five hundred seventy-nine patients who were discharged from the hospital after being started on warfarin therapy.
MEASUREMENTS AND MAIN RESULTS: The primary outcome variable was major hemorrhage. In our cohort of 579 patients, there were 40 first-time major hemorrhages with only one fatal bleed. The cumulative incidence was 7% at 1 year. The average monthly incidence of major hemorrhage was 0.82% during the first 3 months of treatment and decreased to 0.36% thereafter. Three independent predictors of major hemorrhage were identified: a history of alcohol abuse, chronic renal insufficiency, and a previous gastrointestinal bleed. Age, comorbidities, medications known to influence prothrombin levels, and baseline laboratory values were not associated with major hemorrhage.
CONCLUSIONS: The incidence of major hemorrhage in this population of outpatients treated with warfarin was lower than previous estimates of major hemorrhage measured before the recommendation for reduced-intensity anticoagulation therapy was made, but still higher than estimates reported from clinical trials. Alcohol abuse, chronic renal insufficiency, and a previous gastrointestinal bleed were associated with increased risk of major hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613886      PMCID: PMC1496955          DOI: 10.1046/j.1525-1497.1998.00096.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  16 in total

1.  The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic.

Authors:  H I Bussey; R M Rospond; C M Quandt; G M Clark
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

2.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

3.  The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy.

Authors:  C S Landefeld; P A Anderson; L T Goodnough; T W Moir; D L Hom; M W Rosenblatt; L Goldman
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

4.  Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage.

Authors:  D B Petitti; B L Strom; K L Melmon
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

5.  A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment.

Authors:  J C Forfar
Journal:  Br Heart J       Date:  1979-08

6.  Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients.

Authors:  J Launbjerg; H Egeblad; J Heaf; N H Nielsen; A M Fugleholm; K Ladefoged
Journal:  J Intern Med       Date:  1991-04       Impact factor: 8.989

7.  The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.

Authors:  S D Fihn; C M Callahan; D C Martin; M B McDonell; J G Henikoff; R H White
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

8.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

9.  Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin.

Authors:  D B Petitti; B L Strom; K L Melmon
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

10.  Age-related risks of long-term oral anticoagulant therapy.

Authors:  J H Gurwitz; R J Goldberg; A Holden; N Knapic; J Ansell
Journal:  Arch Intern Med       Date:  1988-08
View more
  31 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.

Authors:  J B Segal; R L McNamara; M R Miller; N Kim; S N Goodman; N R Powe; K A Robinson; E B Bass
Journal:  J Gen Intern Med       Date:  2000-01       Impact factor: 5.128

3.  Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients.

Authors:  Unnum Chowdhry; Amanda Jacques; Alan Karovitch; Pierre Giguère; My-Linh Nguyen
Journal:  Can J Hosp Pharm       Date:  2016-06-30

4.  Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.

Authors:  Margaret C Fang; Alan S Go; Elaine M Hylek; Yuchiao Chang; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

5.  Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.

Authors:  Ryan M Carnahan; Joshua J Gagne; Christian Hampp; Charles E Leonard; Sengwee Toh; Candace C Fuller; Sean Hennessy; Laura Hou; Noelle M Cocoros; Genna Panucci; Tiffany Woodworth; Austin Cosgrove; Aarthi Iyer; Elizabeth A Chrischilles
Journal:  Pharmaceut Med       Date:  2019-02

Review 6.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

7.  Pharmacogenetics of anticoagulants.

Authors:  Anders Rane; Jonatan D Lindh
Journal:  Hum Genomics Proteomics       Date:  2010-09-13

8.  Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

Authors:  Kevin E Chan; J Michael Lazarus; Ravi Thadhani; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

9.  Femoral vascular complications following catheter ablation of atrial fibrillation.

Authors:  Liza A Prudente; J Randall Moorman; Douglas Lake; Yuping Xiao; Heather Greebaum; J Michael Mangrum; John P DiMarco; John D Ferguson
Journal:  J Interv Card Electrophysiol       Date:  2009-04-22       Impact factor: 1.900

10.  Potentially avoidable inpatient nights among warfarin receiving patients; an audit of a single university teaching hospital.

Authors:  Dónall Forde; Mortimer B O'Connor; Oonagh Gilligan
Journal:  BMC Res Notes       Date:  2009-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.